Bender Robert & Associates Biocryst Pharmaceuticals Inc Transaction History

Bender Robert & Associates

  • $471 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 13, 2023
SELL
$6.71 - $7.92 $80,520 - $95,040
-12,000 Reduced 17.49%
56,600 $400,000
Q1 2023

Apr 20, 2023
BUY
$7.94 - $11.84 $544,684 - $812,224
68,600 New
68,600 $572,000
Q2 2022

Jul 19, 2022
BUY
$7.89 - $17.88 $541,254 - $1.23 Million
68,600 New
68,600 $726,000

Others Institutions Holding BCRX

# of Institutions
278
Shares Held
172M
Call Options Held
625K
Put Options Held
739K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Bender Robert & Associates Portfolio

Follow Bender Robert & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Bender Robert & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email